rais pt base
growth oper leverag
close report result ahead estim
reiter guidanc test revenu call
season typic result slower sequenti growth importantli test
volum growth top estim allay concern soft
strong case recent technolog acquisit would integr support
test volum growth lower cog expand content base result
greater convict sustain posit low-cost provid
rais revenu forecast also rais pt
result top-line report revenu vs
estim street consensu upsid driven
exclus test volum growth exceed forecast
rais test volum forecast guidanc
account beat healthier growth
season leav leap faith note season weak
test volum growth histor appli similar trend
impli sequenti test growth meet guidanc
believ posit industri season well establish view achiev
magnitud growth impli guidanc may aggress
acquisit rais long-term growth profil last two month
acquir singular jungla offer potenti significantli
lower cog solidifi competit posit expect deal
immedi impact earn warrant re-rat compani long-
term growth outlook view
revis long-term revenu outlook rais revenu forecast
respect
base strong result invest expand sale forc believ
compani begin demonstr meaning cross-sel
reproduct oncolog screen pharma segment lead
sustain test volum growth
increas pt increas pt continu valu
price-to-sal basi estim revenu discount back one year
rais target multipl revenu
partial off-set higher share count million vs
year price histori
diagnost test hereditari cancer
screen famili health plan
variou genet disord provid
predict prognost data
analyst certif import disclosur see disclosur
demand diagnost test unlik much healthcar
signific price elast use genom test
expand price sequenc declin best
posit test provid take advantag thesi base
grow economi scale commit drive
cog price lower singl price regardless breadth
genom data deliv breadth test menu
expect model result prefer access payer
relat market share gain upsid street revenu outlook
beyond
nipt test offer limit differenti account low single-
digit percentag sale
medicar reimburs ngs-base test
code unchang level outlin pama
gradual consolid hereditari cancer test market
continu industri remain highli fragment anoth
new collabor pharmaceut compani improv
test access patient suspect harbor rare diseas
addit partnership pharmaceut compani speed
adopt genom screen rare diseas popul
nipt offer meaning revenu contribut base
strength commerci channel
bolt-on acquisit acceler time-to-profit expand
propos medicar fee schedul cut reimburs ngs-
growth reproduct health non-oncolog indic
stall uptak earli adopt translat broad
genet test wide use cancer prenat care
pace adopt cardiovascular diseas immunolog
condit may slower anticip
pt base price-to-sal analysi assum multipl estim revenu million share
outstand discount back one year cost capit
risk reduct reimburs rate ngs-base genet test disrupt laboratori oper san francisco
facil result delay deliveri test result delay launch new product includ nipt neg impact revenu
growth failur fulli integr recent acquisit result reduc product lower return capit inabl
meet undisclos revenu coven relat debt facil
revenu revenu increas y-o-i estim
street consensu test volum quarter total
y-o-i estim report revenu per test total
quarter exclud one-tim uptsick medicar
payment ofr hboc del/dup compar figur
gross margin gross margin compar year ago
forecast cog prior year
cog manag attribut increas cost
associ bring new product on-line
 administr expens increas report basi treat
total one-tim merger expens exclud one-tim expens
 increas estim
 sell expens increas line estim
growth due higher test volum
 research spend increas vs forecast upsid
forcast primarili post-merg acquist integr expens
increas core spend relat higher softwar engine cost
ep net ep estim consensu
consensu
compani report oppenheim co inc estim
million except per opco estimate genet sell research profit interest incom profit loss per share continu incom loss loss per share averag common invita corp
revenu increas test volum outlook
reduc estim total revenu base
lower balanc due mix shift toward patient initi test
nip mention rais revenu forecast
respect due higher test volum
estim vs prior estim
higher estim primarili relat effici cross-sel nvta
gross margin estim gross margin remain larg increas
modestli estim unchang
 increas estim account
upsid busi develop expeans estim
go respect
increas primarili relat higher headcount relat stock-bas
sell market increas sell expens estim
due expect begin explor modest direct-to-consum
market pilot support patient iniait test
 ad per quarter expens account singular
quarter addit relat
time base oper mileston payment associ transact
increas project expens
total increas
ep net revis ep forecast prior
estim prior consensu increas loss primarili
associ non-cash expens singular transact
ep goe
compani report oppenheim co inc estim
reiter guidanc reiter guidanc
sampl revenu payment third-parti
payer account revenu remaind institut
includ pharma partner patient pay
manag note test volum total full year guidanc slightli ahead
guidanc
reproduct continu see uptak nip account
previous order carrier test manag expect signific contribut
revenu robust growth manag note nip test volum put
upward pressur cog near term
payer access juli compani unitedhealthcar
prefer lab network nvta commerci insur coverag includ
approxim million live network
acquisit relat expens oper expens
increment expens attribut growth base
busi includ increas salesforc headcount higher cost
remain attribut stock-bas compens due
annual retent meet mileston stock-bas compens
singular employe one-tim expens acceler option
singular transact legal fee close singular jungla
genet sell research profit incom profit loss per share continu incom loss loss per share averag common analysisgross invita corp
manag note strong volum intern market
continu account around diagnost test volum go forward
manag primarili focu area alreadi consum base
includ northern europ latin america israel apac region addit
grow overal salesforc headcount look add language-cap member
support intern market china japan central europ near-term
pharma partnership ad addit partnership program
network quarter bring network biopharma partner
